The development of cancer drugs begins with the identification of potential targets, which are usually specific proteins or genes involved in cancer cell survival and proliferation. This is followed by the discovery of compounds that can interact with these targets. These compounds undergo rigorous preclinical testing in laboratories and animal models to evaluate their efficacy and safety.
